Nasdaq, S&P 500 Rally To New Highs After Fed Meeting
at Investor's Business Daily - Wed Jun 18, 3:20PM CDT
The major averages rallied after the Fed said it would keep interest rates near zero and trimmed monthly bond purchases by $10 billion, to $35 billion. The Fed lowered its 2014 economic growth forecast to between 2.1% and 2.3%, from 2.9%, but said...
Stocks Open Mixed In Firm Trade; Adobe, FedEx, Air Products Jump
at Investor's Business Daily - Wed Jun 18, 9:33AM CDT
Stocks churned out a mixed open Wednesday as earnings reports fueled some significant early moves. The Nasdaq slipped 0.2%. The Dow Jones industrial average was down 0.1%. The S&P 500 hung on to a fractional gain. Investor attention on the stock...
Research and Markets: Global IV Iron Drugs Market Report: 2014 Edition
Business Wire - Wed Jun 18, 8:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qdwk3z/global_iv_iron) has announced the addition of the "Global IV Iron Drugs Market Report: 2014 Edition" report to their offering.
Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
at Investor's Business Daily - Wed Jun 18, 7:02AM CDT
With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm -- or face, in the case of Botox maker Allergan (AGN). But not all offers have been...
2014 Report on the International Human Reproductive Technologies Market - Forecast to 2019
M2 - Wed Jun 18, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d66cdt/human) has announced the addition of the "2014 Report on the International Human Reproductive Technologies Market - Forecast to 2019" report to their offering. This report covers the market analysis for various drugs, devices and treatment technologies used in assistance and to control human reproduction. The stakeholders for this study include manufacturers and providers of contraceptive technologies and infertility solutions. The market overview section of the report demonstrates the market dynamics and trends such as the drivers, restraints and opportunities that influence the current nature and future status of this field. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global human reproductive technologies market. The global human reproductive technologies market is categorized on the basis of various infertility treatments and contraceptive technologies. The infertility technologies market is analyzed in this report with respect to drugs as well as types of treatment procedures. With respect to drugs, the report includes leading brands (by sales) from three major classes, namely, gonadotropins, androgens and erectile dysfunction. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Human Reproduction Technologies Market, by Infertility Treatment Chapter 5 Global Human Reproductive Technologies Market, by Contraceptive Technologies Chapter 6 Global Human Reproductive Technologies Market Revenue, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc. - Actavis, Inc. - Bayer AG - Church & Dwight, Co. Inc. - Cook Medical, Inc. - Ferring International Center S.A. - Johnson & Johnson - Merck & Co., Inc. - Merck Serono - Pfizer, Inc. - Reckitt Benckiser Group plc - Teva Pharmaceutical Industries Ltd. - Warner Chilcott plc For more information visit http://www.researchandmarkets.com/research/d66cdt/human
Global IV Iron Drugs Market Report: 2014 Edition
M2 - Wed Jun 18, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/knfh2j/global_iv_iron) has announced the addition of the "Global IV Iron Drugs Market Report: 2014 Edition" report to their offering. The report analyzes the global iron products industry along with an extensive coverage of global and the US IV iron market. The global IV iron market witnesses intense competition with numerous top notch players; such as Galenica Pharmaceuticals, Actavis Inc, AMAG Pharmaceuticals; operating in the marketplace along with small budding players. As a part of analysis of fierce competition prevailing in the industry, product contention has been presented in the report. The company profiles of leading aforementioned players in the market are also incorporated in the report. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron. The key factors driving growth of the global IV iron industry include escalating number of dialysis and hypertension cases, ameliorating economic conditions, increasing global healthcare expenditures, and rising medicines expenditures. Some of the noteworthy trends and developments of this industry encompass novel product development, bundled payment systems and increasing penetration of genecology sector. However, the growth of this industrial sector is being hindered by stringent regulatory structures and adverse affects associated with the use of IV iron products. Key Topics Covered: 1. Iron in Human Body: An Overview 2. Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - AMAG Pharmaceuticals - Actavis Inc. - Galenica Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/kn...al_iv_iron
Actavis' shareholders approves planned acquisition of Forest for about USD25bn in cash and stock
M2 - Wed Jun 18, 3:52AM CDT
Specialist pharmaceutical company Actavis (NYSE:ACT) stated on Tuesday that all proposals related to its planned acquisition of Forest Laboratories (NYSE:FRX) were approved by their respective shareholders at the recent shareholder meetings.
Actavis and Forest Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Forest
Business Wire - Tue Jun 17, 3:17PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that, at shareholder meetings held today, all proposals related to Actavis' planned acquisition of Forest were approved by both Actavis' and Forest's shareholders.
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors
Business Wire - Tue Jun 17, 7:01AM CDT
Cardax, Inc. ("Cardax"
Actavis Strives To Reduce Borrowing Costs
at Investor's Business Daily - Fri Jun 13, 5:48PM CDT
Generic, branded and biosimilar drugmaker Actavis (ACT) may be well-known among investors as a company that has used large acquisitions as one method to boost its earnings and sales sharply. Yet less attention perhaps has been paid to its savvy...
Will Forest Labs Retain Namenda Market Share? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 11:00AM CDT
Forest Laboratories, Inc. (FRX) has postponed the final phase of switching to late 2014 and intends to continue marketing Namenda IR till the fall of 2014.
Actavis Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Forest Laboratories Senior Notes
PR Newswire - Thu Jun 12, 5:16PM CDT
Actavis plc (NYSE: ACT) today announced that Forest Laboratories, Inc. (NYSE: FRX) has received valid consents (the "Requisite Consents"
Forest Laboratories, Inc. Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes
Business Wire - Thu Jun 12, 4:00PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it had received valid consents (the "Requisite Consents"
VIVUS Files Lawsuit Against Actavis for Infringement of Qsymia Patents
Marketwire - Thu Jun 12, 3:33PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories FL, Inc., Actavis, Inc., and Actavis PLC, collectively referred to as Actavis.
Worldwide IV Iron Drugs Industry Analysis and 2018 Forecasts New Research Study Available at MarketReportsOnline.com
PRWeb - Thu Jun 12, 4:03AM CDT
Intravenous (IV) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. Also, this method ensures 100% bioavailability, which means that the chemicals delivered are fully absorbed by the body. The first iron product for intravenous use was high-molecular-weight iron dextran. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron.
Today's Top Performers In Health Care
at The Street - Wed Jun 11, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Actavis to close USD3.7bn senior unsecured notes on 19 June 2014
M2 - Wed Jun 11, 4:51AM CDT
Pharmaceutical company Actavis (NYSE:ACT) said on Tuesday that its Actavis Funding SCS indirect subsidiary has priced its total aggregate offering of USD3.7bn senior unsecured notes 19 June 2014.
Actavis, BitAuto Among Leading World Stocks In Bases
at Investor's Business Daily - Tue Jun 10, 5:50PM CDT
Six of the 10 stocks listed on the Top World Stocks list in Tuesday's IBD are pecking away at new highs. Some are still in buying range after clearing bases. Four others are building bases. One minor catch: They are all late-stage patterns. Late...
Actavis Prices $3.7 Billion of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 4:19PM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to close on June 19, 2014, subject to market conditions and other factors.